Pfizer Greenhouse Gas Emission Reduction Goal辉瑞温室气体减排目标.pptVIP

Pfizer Greenhouse Gas Management ProgramExperience Agenda Rationale for Voluntary Goal Lessons Learned from EU Markets Feasibility of Trading with Kyoto Signatories Company Profile $45 B in global pharmaceutical sales in 2003 $ 7 B biomedical research spend in 2003 Product sales in 150 countries 81 Manufacturing plants in 32 countries 122,000 Colleagues (32,000 in mfg.) More than 25 languages Top-tier Consumer and Animal Health Groups U.S. EPA Climate Leaders Experience with EU ETS Kyoto Protocol EC and Member States committed to reduction of 8% below 1990 GHG levels by 2008 - 2012 Primary driver for EU to develop its regulatory scheme EU Emission Trading Scheme (EU ETS) Cap and Trade of CO2 for large facilities Carbon tax to be imposed on all other facilities Option for small facilities to join ETS and avoid tax (“opt in” provision) Will require detailed financial analysis Member States developing trading guidelines Other “carbon” taxes on fuels being applied by specific Member States, separate from EU ETS EU ETS Regulatory Timetable EU ETS key issues: Direct vs. Indirect Emissions Reduction of direct emissions at facilities expensive Provides no added incentive for demand-side management Windfall for electric generators? How will new entrants be treated? High indirect costs due to higher energy costs and carbon taxes (anti-competitive) Opt-in for unregulated facilities Guidance on trading limited No central market clearinghouse established Unclear if price signal will lead to greater innovation National Allocation Plans (NAPs) not finalized yet GHG Emissions Allocations Carbon Trading Feasibility Outside US Active global markets US firms may purchase credits but may not sell credits generated in US Most reduction opportunities for Pfizer in US No incentive to participate Summary Sustainable Energy Roundtable Series January, 2005 Joined in May, 2002 Established Public Goal May, 2003 Dow Jones Sustainability Index (DJSAM) score for Climate Strategy